KORU Medical Systems (NASDAQ:KRMD – Free Report) had its price target upped by Craig Hallum from $4.00 to $5.00 in a research note issued to investors on Thursday,Benzinga reports. Craig Hallum currently has a buy rating on the stock.
Several other research firms have also recently issued reports on KRMD. B. Riley started coverage on KORU Medical Systems in a research report on Thursday, July 25th. They issued a “buy” rating and a $4.00 price objective for the company. Piper Sandler raised their target price on shares of KORU Medical Systems from $3.00 to $3.50 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Canaccord Genuity Group lifted their price target on shares of KORU Medical Systems from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Thursday.
View Our Latest Stock Report on KORU Medical Systems
KORU Medical Systems Stock Up 2.9 %
Institutional Trading of KORU Medical Systems
Institutional investors and hedge funds have recently bought and sold shares of the stock. Aaron Wealth Advisors LLC bought a new stake in KORU Medical Systems during the second quarter worth approximately $28,000. Allspring Global Investments Holdings LLC bought a new stake in KORU Medical Systems in the 2nd quarter valued at $28,000. XTX Topco Ltd bought a new stake in shares of KORU Medical Systems during the 3rd quarter valued at $34,000. Legato Capital Management LLC acquired a new position in KORU Medical Systems in the 2nd quarter worth about $35,000. Finally, Virtu Financial LLC acquired a new stake in shares of KORU Medical Systems in the first quarter valued at about $63,000. Institutional investors and hedge funds own 58.60% of the company’s stock.
KORU Medical Systems Company Profile
KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.
Further Reading
- Five stocks we like better than KORU Medical Systems
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- The Risks of Owning Bonds
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Time to Load Up on Home Builders?
Receive News & Ratings for KORU Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KORU Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.